Table S1.
Adverse events for patients receiving IFN-based therapy (n=30)
| Adverse events (per patient), mean ± SD 14.4±3.76 | ||
|---|---|---|
| Adverse events requiring medical treatment (per patient), mean ± SD 2.2±2.16 | ||
|
| ||
| Common adverse event | Patients, n (%) | Requiring medical treatment, n (%)a |
| Fatigue | 24 (80) | 0 |
| Rash | 22 (73.3) | 13 (59.1) |
| Mood change | 22 (73.3) | 3 (13.6) |
| Depression | 9 (30) | 2 (22.2) |
| Irritability | 16 (53.3) | 1 (6.25) |
| Pruritus | 18 (60) | 0 |
| Upper respiratory tract symptoms | 16 (53.3) | 4 (25) |
| Weight loss | 15 (50) | 0 |
| Headache | 14 (46.7) | 0 |
| Sleep disturbance | 12 (40) | 5 (41.7) |
| Flu-like symptoms (non-specific) | 12 (40) | 0 |
| Myalgia | 11 (36.7) | 0 |
| Severe hematological adverse event | ||
| Hemoglobin | ||
| Hb 80–99 (gL−1) | 9 (30) | 1 (11.1) |
| Hb <80 (gL−1) | 1 (3.3) | 0 |
| Neutrophils | ||
| 0.5–0.99 (×109 L−1) | 17 (56.6) | 0 |
| <0.5 (×109 L−1) | 3 (10) | 0 |
| Platelets | ||
| 50–99 (×109 L−1) | 12 (40) | 0 |
| <50 (×109 L−1) | 2 (6.7) | 1 (50) |
| Serious adverse events (requiring hospital admission) | 2 (6.7) | 2 (100) |
| Immune thrombocytopenic purpura | 1 (3.3) | 1 (100) |
| Osteomyelitis | 1 (3.3) | 1 (100) |
Note:
a
Percentage of total number of patients who experienced the adverse event.
Abbreviations: Hb, hemoglobin; IFN, interferon.